Why Is Accelerant (ARX) Up 43%? A 49% Premium Below the IPO Price

TL;DR

• Thoma Bravo is buying Accelerant in an all-cash deal at $20.25 a share, a 49% premium to Wednesday's $13.61 close, with an enterprise value the parties put at more than $4 billion.
• ARX quoted $19.46 at about 1:55pm ET, up 42.98%. The session was still running when this published.
• The IPO was $21.00 on July 24 2025. Thirteen months later the exit price is 3.6% below where the shares came public, and 34% below the $30.48 they touched afterwards.
• Altamont Capital Partners controls about 82% of the voting rights and has signed up to vote yes. The shareholder vote is arithmetic, not a contest.
• The spread is 4.1% against a close guided to the first half of 2027. Break risk takes the stock back toward $13.61. I don't like that trade.

Why Is Accelerant Stock Up?

Accelerant agreed to be taken private by Thoma Bravo at $20.25 a share in cash, announced Thursday morning alongside Q2 results. The Thoma Bravo release puts the premium at 49% over the August 12 close and the enterprise value at more than $4 billion. There is no financing condition; Thoma Bravo has posted an equity commitment for the full amount.

The stock was quoted at $19.46 around 1:55pm ET, up 42.98% on a $13.61 Wednesday close.

Several write-ups on Thursday attributed the move to the earnings beat that landed the same morning. The earnings were fine. They are not why the stock is up 43%, and anyone reading a "+100% EPS surprise" headline as the catalyst has the wrong story.

The Board

A 49% premium and a price below the IPO are the same number seen from two ends of thirteen months.

Thirteen Months, Round Trip

Accelerant priced an upsized IPO at $21.00 on July 24 2025 and jumped about 35% on debut. It ran to $30.48 at its best. It bottomed at $9.18. Wednesday it closed at $13.61, and Thursday a private equity firm agreed to pay $20.25 for the whole thing.

So the headline premium is real and the exit is still below the entry. Anyone who bought the IPO at $21 and holds to close collects $20.25 and a year of nothing. Anyone who bought at $9.18 in the drawdown more than doubles. Both statements come off the same deal price, which is why "49% premium" on its own tells a reader very little.

I'd note the shape here matches the Mapfre bid for Safety Insurance more than it matches the Ardagh sale process published this morning. Ardagh has an adviser mandate. Accelerant has a signed agreement, a named price and a board recommendation, and the market repriced it in one session accordingly.

The Vote Is Already Counted

Altamont Capital Partners entities hold shares carrying roughly 82% of outstanding voting rights and have agreed to vote in favour. Altamont and the founders also intend to retain equity alongside Thoma Bravo, with terms to be finalised at closing.

A Special Committee of independent directors ran the process and unanimously recommended it; the full board then approved unanimously. Houlihan Lokey advised the committee, Morgan Stanley the company.

That structure settles the question minority holders would otherwise be asking. There is no realistic path where enough public shareholders vote this down to matter. What remains is regulatory, and in specialty insurance that is not trivial: the agreement carries a ticking fee accruing at 6% a year if closing is held up by certain pending insurance regulatory approvals, which is the parties telling you where they expect the friction.

What Q2 Actually Said

The quarter was solid and is now mostly of historical interest, because Accelerant withdrew Q3 and full-year guidance on account of the pending deal.

Exchange Written Premium was $1,322.3m, up 23% from $1,072.3m, against 42% growth in the year-ago quarter. Total revenues were $356.9m versus $219.1m. Net income was $80.0m against $13.1m. Adjusted EBITDA came in at $93.1m, up from $63.6m.

One number needs its denominator named. The company reports a 31% adjusted EBITDA margin, and that is struck against Operating Revenues of $303.9m rather than the $356.9m total revenue line. Divide $93.1m by total revenues and you get 26.1%. Both are defensible; only one is the company's definition, and a reader comparing the margin against the wrong revenue figure will think the release is wrong.

Underneath, the segments are lopsided. Exchange Services did $74m of adjusted EBITDA and MGA Operations $30.3m. Underwriting did $1.9m. The pre-earnings worry was exactly that underwriting profitability would drag, and it did; the fee-based half of the business carried the quarter.

The Arb

The whole trade here is now the spread, so that is what I'll log. At $19.46 against $20.25 there is 4.1% of gross return sitting there, and the parties guide to a close in the first half of 2027. Call it eight months and it annualises near 6%, plus whatever the 6% ticking fee adds if insurance regulators run long.

Against that, a break sends the stock back toward the undisturbed $13.61, which is 30% lower. Risking 30 to make 4 needs the break probability under roughly 12% before it pays, and I am not confident enough in a multi-jurisdiction insurance approval running clean over ten months to underwrite that. The signed agreement, the locked-up 82% and the equity commitment all cut the right way. The tenor does not. My call is to pass.

The options side is simpler. A signed all-cash deal at a fixed price flattens implied volatility and pins the stock under $20.25, so call options struck above the deal price are close to worthless by construction and covered calls collect almost nothing. I could not source a live chain, so nothing is priced below.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Breakeven
1	Pass	Merger arb, long common	Buy $19.46, terms $20.25, close H1 2027	4.1% gross, ~6% annualised at 8 months	$19.46, 1:55pm ET Aug 13	n/a, deal-pinned	$19.46; break risk to $13.61, −30%
2	Pass	Long call	No live chain sourced	n/a	$19.46, 1:55pm ET Aug 13	n/a	Capped at $20.25 by the terms

The One-Line Read

Thoma Bravo is paying a 49% premium and still buying it cheaper than the IPO. The vote is locked, so the only open question is regulatory, and 4% does not pay me to wait ten months for that answer.

The rest of Thursday, PPI and Applied Materials tonight, sits in the August 13 hour-by-hour.